FluGen Announces First Subject Dosed in Phase Ib Clinical Trial of its Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults

FluGen, Inc. announced the dosing of its first subject in an unprecedented study of older adults ages 65-85 years that will evaluate the safety, tolerability, and immunological response to FluGen’s investigational supra-seasonal, live, single-replication, intranasal M2SR influenza vaccine, and high dose inactivated vaccine